FILE 'REGISTRY' ENTERED AT 14:24:10 ON 17 MAR 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2006 HIGHEST RN 877033-93-7
DICTIONARY FILE UPDATES: 15 MAR 2006 HIGHEST RN 877033-93-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
                E SPM 4757/CN
L1            2 S E6-7
                E "SP/W 4757"/CN 5
L2            2 S E1 OR E6
L3            4 S L1 OR L2
```

L3 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
RN 316365-71-6 REGISTRY
ED Entered STN: 24 Jan 2001
CN L-Cysteine, N-(3-hydroxy-2,2-dimethyl-1-oxopropyl)-, ethyl ester, 3-[(acetylamino)acetate] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **SP/W 6373**
FS STEREOSEARCH
MF C14 H24 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
RN 139146-66-0 REGISTRY
ED Entered STN: 21 Feb 1992
CN L-Cysteine, N-[2,2-dimethyl-3-(nitrooxy)-1-oxopropyl]-, ethyl ester, ester with N-acetyl-L-alanine (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **SPM 5185**
FS STEREOSEARCH
MF C15 H25 N3 O8 S
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
RN 139146-65-9 REGISTRY
ED Entered STN: 21 Feb 1992
CN L-Cysteine, N-[2,2-dimethyl-3-(nitrooxy)-1-oxopropyl]-, ethyl ester, ester with N-acetylglycine (9CI) (CA INDEX NAME)
OTHER NAMES:

CN SP/W 5186
CN **SPM 5186**
FS STEREOSEARCH
MF C14 H23 N3 O8 S
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CIN, PHAR, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
RN 130432-17-6 REGISTRY
ED ~~Entered STN:~~ 16 Nov 1990
CN L-Cysteine, N-[2,2-dimethyl-3-(nitrooxy)-1-oxopropyl]-, ethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **SP/W 3672**
CN SPM 3672
FS STEREOSEARCH
MF C10 H18 N2 O6 S
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, EMBASE, IMSRESEARCH, MEDLINE, PROUSDDR, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

FILE 'CAPLUS' ENTERED AT 14:24:11 ON 17 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Mar 2006 VOL 144 ISS 13
FILE LAST UPDATED: 16 Mar 2006 (20060316/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

L1	2	SEA FILE=REGISTRY ABB=ON PLU=ON ("SPM 5185"/CN OR "SPM 5186"/CN)
L2	2	SEA FILE=REGISTRY ABB=ON PLU=ON "SP/W 3672"/CN OR "SP/W 6373"/CN
L3	4	SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2
L4	39	SEA FILE=CAPLUS ABB=ON PLU=ON L3 OR SPM4757 OR SPM5186 OR SPM5185 OR SPM3672 OR SPM6373 OR SPW4757 OR SPW5186 OR SPW3672 OR SPW6373 OR (SPM OR SP(W)W OR SPW)(W)(4757 OR 5186 OR 5185 OR 3672 OR 6373)
L5	3	SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND (GASTROINTESTIN? OR ULCER? OR GASTR? INTESTIN?)

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Feb 2003
ACCESSION NUMBER: 2003:132965 CAPLUS
DOCUMENT NUMBER: 138:163603
TITLE: Methods for novel sulfur-containing organic nitrate compounds use in the treatment and prevention of human diseases and conditions
INVENTOR(S): Garvey, David S.; Letts, L. Gordon
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013432	A2	20030220	WO 2002-US24923	20020807

WO 2003013432 A3 20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2453433	AA	20030220	CA 2002-2453433	20020807
EP 1414432	A2	20040506	EP 2002-786354	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005501060	T2	20050113	JP 2003-518446	20020807
US 2004152753	A1	20040805	US 2004-760672	20040121
PRIORITY APPLN. INFO.:			US 2001-311715P P	20010810
			WO 2002-US24923 W	20020807

OTHER SOURCE(S): MARPAT 138:163603

AB The invention describes methods of use for an organic nitrate compound, or a pharmaceutically acceptable salt thereof, wherein the organic nitrate compound comprises at least one sulfur atom and/or at least one disulfide group. The invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; for decreasing or reversing the **gastrointestinal**, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory compds.; for treating and/or preventing **gastrointestinal** disorders; for treating inflammatory disease states and disorders; for treating and/or preventing ophthalmic diseases or disorders; for treating and/or improving the **gastrointestinal** properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; for decreasing the recurrence of **ulcers**; for improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; for treating Helicobacter pylori and viral infections. For improving gastroprotective properties of Hz receptor antagonists; for treating and/or preventing inflammations and microbial infections, multiple sclerosis, and viral infections; for treating or preventing restenosis, autoimmune diseases, pathol. conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory diseases or to inhibit wound contraction; for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females; for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina , glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, and overactive bladder; for reversing the state of anesthesia. For treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3',5'-monophosphate (cGMP); for treating respiratory disorders and for treating neurol. conditions.

IT **130432-17-6, SPM 3672 139146-65-9 , SPM 5186 139146-66-0, SPM 5185**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(methods for novel sulfur-containing organic nitrate compds. use in the treatment and prevention of human diseases and conditions)

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Nov 2002
ACCESSION NUMBER: 2002:864914 CAPLUS
DOCUMENT NUMBER: 138:395694
TITLE: NO-donors (VII [1]): synthesis and cyclooxygenase inhibitory properties of N- and S-nitrooxypivaloyl-cysteine derivatives of naproxen - a novel type of NO-NSAID
AUTHOR(S): Kartasasmita, Rahmana E.; Laufer, Stefan; Lehmann, Jochen
CORPORATE SOURCE: Institute of Pharmacy, University of Bonn, Bonn, D-53121, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2002), 335(8), 363-366
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Nitric oxide (NO) has been reported to subserve many of the same mucosal protection mechanisms as prostaglandins and is sufficient for acute gastroprotection and **ulcer** healing. In fact, NO-donating NSAID hybrid compds. such as the nitrooxybutyl ester of naproxen show reduced **ulcerogenic** activity while maintaining anti-inflammatory activity. We introduce two prototypes of novel triple-hybrid compds. consisting of cysteine which is known to enhance the activity of organic nitrates and to reduce nitrate tolerance, an NSAID (naproxen), and an organic nitrate (nitrooxypivaloic acid). L-Cysteine Et ester first was N-acylated in a CH2Cl2/H2O two-phase system using the acid chlorides of naproxen or nitrooxypivaloic acid, resp., and sodium acetate, or alternatively using the DCC-activated nitrooxy acid in absolute CH2Cl2. The N-acylated intermediates were subsequently S-acylated using the acid chlorides or alternatively the carbonyldiimidazole (CDI)-activated acids again. The two naproxen-cysteine-nitrate hybrid prodrugs were screened in vitro for their cyclooxygenase inhibitory properties relative to naproxen. In this screening the N-nitrooxyacylcysteine derivative was found to be inactive in the concentration range of 0.1-10 μmol/L against both COX-1 and COX-2, while the S-nitrooxyacylcysteine derivative had only weak activity against COX-1.
IT **130432-17-6P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and cyclooxygenase inhibitory properties of novel NO-NSAID nitrooxypivaloyl-cysteine derivs. of naproxen)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Nov 2000
ACCESSION NUMBER: 2000:785898 CAPLUS
DOCUMENT NUMBER: 133:329627
TITLE: Tetracyclic cGMP-specific phosphodiesterase inhibitors and their use in disease treatment
INVENTOR(S): Daugan, Alain Claude Marie; Gellibert, Francoise

Searcher : Shears 571-272-2528

PATENT ASSIGNEE(S): Icos Corp., USA
SOURCE: U.S., 30 pp., Cont.-in-part of PCT 9519978.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6143746	A	20001107	US 1998-154051	19980916
WO 9519978	A1	19950727	WO 1995-EP183	19950119
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9703675	A1	19970206	WO 1996-EP3024	19960711
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
WO 9703985	A1	19970206	WO 1996-EP3025	19960711
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 6025494	A	20000215	US 1998-133078	19980812
CA 2340636	AA	20000323	CA 1999-2340636	19990826
EP 1113800	A1	20010711	EP 1999-945201	19990826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002524516	T2	20020806	JP 2000-569812	19990826
US 6127542	A	20001003	US 1999-399667	19990921
US 6369059	B1	20020409	US 2000-633431	20000807
CZ 289832	B6	20020417	CZ 2000-3428	20000919
US 2002119976	A1	20020829	US 2002-68114	20020205
US 6784179	B2	20040831		
JP 2004217674	A2	20040805	JP 2004-125881	20040421

PRIORITY APPLN. INFO.:

GB 1994-1090	A	19940121
WO 1995-EP183	A2	19950119
GB 1995-14464	A	19950714
GB 1995-14465	A	19950714
WO 1996-EP3024	A2	19960711
WO 1996-EP3025	A2	19960711
JP 1995-519339	A3	19950119

CZ 1998-33	A3	19960711
US 1996-669389	A3	19960716
US 1998-133078	A1	19980812
US 1998-154051	A	19980916
WO 1999-US19466	W	19990826
US 1999-399667	A1	19990921
US 2000-633431	A1	20000807

OTHER SOURCE(S): MARPAT 133:329627
GI



I

AB A compound of formula I (R0 = H, halogen, C1-6 alkyl; R1 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo-C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-3 alkyl, aryl-C1-3 alkyl, heteroaryl-C1-3 alkyl; R2 = (substituted) monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or (substituted) bicyclic ring (a) attached to the rest of the mol. via one of the benzene ring carbon atoms, and wherein the fused ring is a 5- or 6-membered ring which may be saturated or partially or fully unsatd., and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; R3 = H, C1-3 alkyl, or R1 and R3 together = 3- or 4-membered alkyl or alkenyl chain) and salts and solvates thereof is disclosed. Compound I is a potent and selective inhibitor of cyclic guanosine 3',5'-monophosphate-specific phosphodiesterase, having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction. Thus, many I compds. were synthesized and tested in vitro as inhibitors of cGMP phosphodiesterase. Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione showed IC50 of 10 nM.

Cl. 1 & 12
Claim col. 9 l. 35 ∅

IT **130432-17-6** SPM 3672 Form II
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug containing phosphodiesterase inhibitor and; tetracyclic cyclic GMP-specific phosphodiesterase inhibitors and their use in disease treatment)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'MEDLINE' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'BIOSIS' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'EMBASE' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'WPIDS' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'CONFSCI' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'SCISEARCH' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'JICST-EPLUS' ENTERED AT 14:29:43 ON 17 MAR 2006

FILE 'JAPIO' ENTERED AT 14:29:43 ON 17 MAR 2006

L6 0 S L5

(FILE 'CAPLUS' ENTERED AT 14:30:07 ON 17 MAR 2006)
L7 9 SEA FILE=CAPLUS ABB=ON PLU=ON (NITRATOPIVAL? OR NITRATO PIVAL?)(S)ESTER
L8 0 SEA FILE=CAPLUS ABB=ON PLU=ON L7 AND (GASTROINTESTIN? OR ULCER? OR GASTR? INTESTIN?)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 14:31:13 ON 17 MAR 2006)
L10 56 S L7(S)(ET OR ETHYL)
L11 4 S L10 AND (GASTROINTESTIN? OR ULCER? OR GASTR? INTESTIN?)
L12 4 DUP REM L11 (0 DUPLICATES REMOVED)

L12 ANSWER 1 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-271365 [23] WPIDS
DOC. NO. CPI: C2000-082857
TITLE: New carboline derivatives, useful for treatment of e.g. erectile dysfunction, angina, hypertension, congestive heart failure, stroke, ulcers and dysmenorrhea, are cGMP (cyclic guanosine monophosphate)-specific phosphodiesterase inhibitors.
DERWENT CLASS: B02 C02
INVENTOR(S): BOMBRUN, A; GELLIBERT, F
PATENT ASSIGNEE(S): (ICOS-N) ICOS CORP; (BOMB-I) BOMBRUN A
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000015639	A1	20000323	(200023)*	EN	86
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9910258	A	20000403	(200034)		

BR 9816018 A 20010605 (200138)
EP 1114048 A1 20010711 (200140) EN
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
JP 2002524564 W 20020806 (200266) 75
US 6462047 B1 20021008 (200269)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000015639	A1	WO 1998-EP6050	19980916
AU 9910258	A	WO 1998-EP6050	19980916
		AU 1999-10258	19980916
BR 9816018	A	BR 1998-16018	19980916
		WO 1998-EP6050	19980916
EP 1114048	A1	EP 1998-952629	19980916
		WO 1998-EP6050	19980916
JP 2002524564	W	WO 1998-EP6050	19980916
		JP 2000-570177	19980916
US 6462047	B1	WO 1998-EP6050	19980916
		US 2001-744859	20010516

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9910258	A	Based on	WO 2000015639
BR 9816018	A	Based on	WO 2000015639
EP 1114048	A1	Based on	WO 2000015639
JP 2002524564	W	Based on	WO 2000015639
US 6462047	B1	Based on	WO 2000015639

PRIORITY APPLN. INFO: WO 1998-EP6050 19980916
AN 2000-271365 [23] WPIDS
AB WO 200015639 A UPAB: 20000516
NOVELTY - Carboline derivatives (I), their salts and solvates, are new.

DETAILED DESCRIPTION - Carboline derivatives of formula (I), their salts and solvates, are new.

A = 5 - 6 membered heteroaryl group containing at least 1 heteroatom selected from O, N and S;

R0 = H or halogen;

R1 = H, nitro, trifluoromethyl, trifluoromethoxy, halogen, cyano, 5 - 6 membered heteroaryl group containing at least 1 heteroatom selected from O, N and S, (optionally substituted by C(O)ORa or 1-4C alkyl), 1-6C alkyl optionally substituted by ORa, 1-3C alkoxy, C(O)Ra, OC(O)Ra, C(O)Ra, (1-4C alkylene)-Het, (1-4C alkylene)-C(O)ORa, O-(1-4C alkylene)-C(O)ORa, (1-4C alkylene)-O-(1-4C alkylene)-C(O)ORa, C(O)NRaSO2Rc, C(O)-(1-4C alkylene)-Het, (1-4C alkylene)-NRaRb, (2-6C alkylene)-NRaRb, C(O)NRaRb, C(O)RaRc, C(O)NRa-(1-4C alkylene)-ORb, C(O)NRa-(1-4C alkylene)-Het, ORa, O-(2-4C alkylene)-NRaRb, O-(1-4C alkylene)-Het, O-(2-4C alkylene)-ORa, O-(2-4C alkylene)-NRaC(O)ORb, NRaRb, NRa-(1-4C alkylene)-NRaRb, NRaC(O)Rb, NRaC(O)NRaRb, N(SO2-(1-4C alkyl))2, NRa(SO2-(1-4C alkyl), SO2NRaRb or OSO2CF3;

R2 = H, halogen, ORa, 1-6C alkyl, nitro or NRaRb; or

R1 + R2 = 3 or 4 membered alkylene or alkenylene chain, optionally containing at least 1 heteroatom component of a 5 or 6 membered ring;

R3 = H, halogen, NO2, trifluoromethoxy, 1-6C alkyl, O-(1-6C

alkyl), or C(O)ORa;
R4 = H; or
R3 + R4 = 3 or 4 membered alkylene or alkenylene chain component of a 5 or 6 membered ring, optionally containing at least 1 heteroatom;
Het = 5 or 6 membered heterocyclic group containing at least 1 O, N and/or S, and is optionally substituted by 1-4C alkyl;
Ra, Rb = H or 1-6C alkyl;
Rc = phenyl or 4-6C cycloalkyl, both optionally substituted by 1 or more halogen, C(O)ORa or ORa;
n = 1 - 3; and
m = 1 or 2.

INDEPENDENT CLAIMS are provided for:
(1) a composition comprising (I) and a second active agent for simultaneous, seperate or sequential use; and
(2) a process for the preparation of (I).

ACTIVITY - Vasotropic; centrally active; endocrine; antianginal; hypotensive; respiratory; cytostatic; cardiant; nephrotropic; antiarteriosclerotic; antiaggregant; hemostatic; antiinflammatory; cerebroprotective; antiasthmatic; ophthalmological; antiulcer; **gastrointestinal**; osteopathic; tocolytic; gynecological; analgesic (all claimed)

MECHANISM OF ACTION - Phosphodiesterase V inhibitor; acetylcholine esterase inhibitor; neutral endopeptidase inhibitor; adrenergic antagonist.

(I) were administered to spontaneously hypertensive rats at 5 mg/kg in 5% DMF and 95% olive oil. Blood pressure was measured using a catheter in the carotid artery and recorded for 5 hours post administration. The area under curve for (E)-1R-1-(1-(2,3-dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro- beta -carbolin-2-yl)-3-(pyrrolidin-1-yl)-propen-1-one (Ia) was 9 mm Hg/hour.

USE - As cGMP (cyclic guanosine monophosphate)-specific phosphodiesterase inhibitors for treatment of erectile dysfunction, angina, hypertension, pulmonary or malignant hypertension, COPD (chronic obstructive pulmonary disease), pheochromocytoma, ARDS (not defined), congestive heart failure, renal failure, atherosclerosis, reduced blood vessel patency, peripheral vascular disease, vascular disorder, thrombocythemia, inflammatory disease, myocardial infarction, stroke, bronchitis, asthma, allergic rhinitis, glaucoma, peptic **ulcer**, gut motility disorder, post-percutaneous transluminal coronary angioplasty, carotid angioplasty, post-surgical graft stenosis, osteoporosis, pre-term labor, benign prostatic hypertrophy, female sexual dysfunction, dysmenorrhea and IBS (irritable bowel syndrome) (claimed).

ADVANTAGE - Good oral bioavailability, specific for phosphodiesterase 5.

Dwg.0/0

Come up in Search

L12 ANSWER 2 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2000-271237 [23] WPIDS
CROSS REFERENCE: 1995-275237 [36]; 1997-132562 [12]; 2001-023419 [03]
DOC. NO. CPI: C2000-082747
TITLE: Composition for simultaneous, separate, or sequential use in the treatment of e.g. erectile dysfunction, comprises a tetracyclic phosphodiesterase inhibitor and a second active agent, e.g. vasodilator, acetylcholine esterase inhibitor.
DERWENT CLASS: B05
INVENTOR(S): DAUGAN, A C; GELLIBERT, F

Some Agg's @ 1/4

PATENT ASSIGNEE(S): (ICOS-N) ICOS CORP
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000015228	A1	20000323	(200023)*	EN	89
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW					
AU 9957856	A	20000403	(200034)		
BR 9913824	A	20010619	(200140)		
EP 1113800	A1	20010711	(200140)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002524516	W	20020806	(200266)		84

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000015228	A1	WO 1999-US19466	19990826
AU 9957856	A	AU 1999-57856	19990826
BR 9913824	A	BR 1999-13824	19990826
		WO 1999-US19466	19990826
EP 1113800	A1	EP 1999-945201	19990826
		WO 1999-US19466	19990826
JP 2002524516	W	WO 1999-US19466	19990826
		JP 2000-569812	19990826

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9957856	A	Based on	WO 2000015228
BR 9913824	A	Based on	WO 2000015228
EP 1113800	A1	Based on	WO 2000015228
JP 2002524516	W	Based on	WO 2000015228

PRIORITY APPLN. INFO: US 1998-154051 19980916
AN 2000-271237 [23] WPIDS
CR 1995-275237 [36]; 1997-132562 [12]; 2001-023419 [03]
AB WO 200015228 A UPAB: 20021014
NOVELTY - A composition for the simultaneous, separate or sequential use in the treatment of a condition by inhibition of a cGMP specific phosphodiesterase, comprises a tetracyclic compound (I) and a second therapeutically active agent.

DETAILED DESCRIPTION - A composition for the simultaneous, separate or sequential use in the treatment of a condition by inhibition of a cGMP specific phosphodiesterase, comprises a tetracyclic compound of formula (I), and salts and solvates, and a second therapeutically active agent.

R0 = H, halogen or 1-6C alkyl;

R1 = H, 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, halo-(1-6C)-alkyl, 3-8C cycloalkyl, 3-8C cycloalkyl-(1-3C)-alkyl, aryl-(1-3C)-alkyl or heteroaryl-(1-3C)-alkyl;

R2 = optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, pyridine or an optionally substituted bicyclic ring of formula (i), attached to the rest of the molecule via one of the benzene C atoms;

A = 5 - 6 membered ring optionally containing 1 - 2 O, S and or N; and

R3 = H or 1-3C alkyl; or

R1 + R2 = 3-4C alkyl or 3-4C alkenyl.

ACTIVITY - Vasodilator; antianginal; hypotensive; respiratory; antiatherosclerotic; cardiant; vasotropic; hemostatic; antiinflammatory; cerebroprotective; antiasthmatic; antiallergic; ophthalmological; antiulcer; cytostatic; **gastrointestinal**, CNS active; endocrine.

MECHANISM OF ACTION - Phosphodiesterase inhibitor.

cGMP-PDE (cyclic GMP dependent phosphodiesterase) activity was measured using a one-step assay adapted from Wells et al., Biochim. Biophys. Acta, 384, 430 (1975). The reaction medium contained 50 mM Tris-HCl, pH 7.5, 5 mM magnesium acetate, 250 micro g/ml 5'-nucleotidase, 1 mM EGTA (ethylenebis(oxyethylenenitrolo)tetraacetic acid and 0.15 micro M 8-(H3)-cGMP. The enzyme used was human recombinant PDE-5. (I) were dissolved in DMSO (dimethylsulfoxide) finally present at 2 % in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30 %. Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo(b)-furan-5-yl)-2-methylpyrazine(2',1':6,1)pyrido(3,4-b)indole-1,4-dione (Ia) had an IC50 of less than 10 nM.

USE - The composition is used to treat stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, congestive heart failure, acute respiratory distress syndrome, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, myocardial infarction, post-bypass surgery graft stenosis, a peripheral vascular disease, a vascular disorder, Raynaud's disease, thrombocythemia, an inflammatory disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic **ulcer**, osteoporosis, preterm labor, benign ~~prostatic~~ hypertrophy, a gut motility disorder, irritable bowel syndrome or male or female mammalian erectile dysfunction, preferably erectile dysfunction, especially human erectile dysfunction (claimed).

Dwg.0/0

L12 ANSWER 3 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2001-023419 [03] WPIDS

CROSS REFERENCE: 1995-275237 [36]; 1997-132562 [12]; 2000-271237 [23]

DOC. NO. CPI: C2001-007100

TITLE: Use of hexahydro-pyrazino-pyrido-indole-dione derivative and another drug for treatment of conditions benefiting from cGMP-specific phosphodiesterase inhibition e.g. erectile dysfunction.

DERWENT CLASS: B05 C03

INVENTOR(S): DAUGAN, A C; GELLIBERT, F

PATENT ASSIGNEE(S): (ICOS-N) ICOS CORP

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

US 6143746	A	20001107 (200103)*	30

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 6143746	A CIP of	WO 1995-EP183	19950119
		US 1998-154051	19980916

PRIORITY APPLN. INFO: GB 1995-14474 19950714; GB 1994-1090 19940121; GB 1995-14465 19950714

AN 2001-023419 [03] WPIDS

CR 1995-275237 [36]; 1997-132562 [12]; 2000-271237 [23]

AB US 6143746 A UPAB: 20010116

NOVELTY - A combination of a 2,3,6,7,12,12a-hexahydro-pyrazino(2',1';6,1)pyrido(3,4-b)indole-1,4-dione derivative (I) and another drug (II) is claimed for simultaneous, separate or sequential use in the treatment of conditions where inhibition of cGMP-specific phosphodiesterase (PDE) is of therapeutic benefit.

DETAILED DESCRIPTION - A combination of a 2,3,6,7,12,12a-hexahydro-pyrazino(2',1';6,1)pyrido(3,4-b)indole-1,4-dione of formula (I) and another drug (II) is claimed for simultaneous, separate or sequential use in the treatment of conditions where inhibition of cGMP-specific phosphodiesterase (PDE) is of therapeutic benefit.

R0 = H, halogen or 1-4C alkyl;

R1 = H, 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, 1-6C haloalkyl, 3-8C cycloalkyl, (3-8C)cycloalkyl(1-3C)alkyl, aryl(1-3C)alkyl or heteroaryl(1-3C)alkyl;

R2 = phenyl, thienyl, furyl or pyridyl, where phenyl is optionally fused to a 5- or 6-membered ring containing 0-2 heteroatoms selected from O, S and N; and

R3 = H or 1-3C alkyl; or

R1+R3 = 3-4C alkylene or alkenylene.

ACTIVITY - Vasotropic; antianginal; hypotensive; cardiant; nephrotropic; antiarteriosclerotic; vasotropic; antiinflammatory; cerebroprotective; antiasthmatic; antiallergic; opthalmalogical; antiulcer; osteopathic; laxative; antidiarrheic.

MECHANISM OF ACTION - Phosphodiesterase-5 inhibitor.

The hypotensive effects of (I) and (II) were studied in conscious spontaneously hypertensive rats. Various mixtures of (I) and (II) gave results expressed as Area Under Curve (AUC) from 0-5 hours in mmHg.hours, of the fall in blood pressure over time of 77-171.

USE - The combination is especially useful for treating conditions where inhibition of PDE5 is of therapeutic benefit, in humans or nonhuman animals, especially erectile dysfunction, stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, acute respiratory distress syndrome, malignant hypertension, pheochromocytoma, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, peripheral vascular disease, a vascular disorder, thrombocythemia, inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic **ulcer**, gut motility disorders, post-percutaneous transluminal coronary or carotid angioplasty, post-bypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy or irritable

bowel syndrome.
Dwg.0/0

L12 ANSWER 4 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-282560 [24] WPIDS
CROSS REFERENCE: 1998-076777 [07]
DOC. NO. CPI: C2000-085192
TITLE: Combinations comprising carboline derivatives and second therapeutic agent for simultaneous, separate or sequential treatment of conditions where inhibition of cGMP-specific PDE is of therapeutic benefit.
DERWENT CLASS: B02
INVENTOR(S): BOMBRUN, A
PATENT ASSIGNEE(S): (ICOS-N) ICOS CORP
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6043252	A	20000328	(200024)*		40

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
US 6043252	A	CIP of	WO 1997-EP2277	19970505
			US 1998-154052	19980916

PRIORITY APPLN. INFO: US 1998-154052 19980916; WO 1997-EP2277 19970505
AN 2000-282560 [24] WPIDS
CR 1998-076777 [07]
AB US 6043252 A UPAB: 20000522
NOVELTY - Combinations comprising:
(a) carboline derivatives and their salts and solvates; and
(b) second therapeutically active agent, for simultaneous, separate or sequential use in the treatment of conditions where inhibition of a cyclic-guanylic acid (cGMP)-specific phosphodiesterase (PDE) is of therapeutic benefit.
DETAILED DESCRIPTION - Carboline derivatives in the combination are of formula (I):
R0 = H or halo;
R1 = H, nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, 5-6-membered heterocyclic group containing at least one heteroatom chosen from O, S and N optionally substituted by C(=O)ORa or 1-4C alkyl, 1-6C alkyl optionally substituted by ORa, 1-3C alkoxy, C(=O)Ra, OC(=O)Ra, C(=O)ORa, 1-4C alkylene-C(=O)ORa, O-(1-4C) alkylene-C(=O)ORa, 1-4C alkylene-O-(1-4C) alkylene-C(=O)ORa, C(=O)NRaSO2Rc, C(=O)-(1-4C) alkylene-Het, 1-4C alkylene-NRaRb, 2-6C alkenylene-NRaRb, C(=O)NRaRb, C(=O)NRaRc, C(=O)NRa-(1-4C) alkylene-ORb, C(=O)NRa-(1-4C) alkylene-Het, ORa O-(2-4C) alkylene-NRaRb, O-(1-4C) alkylene-CH(ORa) CH2NRaRb, O-(1-4C) alkylene-Het, O-(2-4C) alkylene-ORa, O-(2-4C) alkylene-NRa-C(=O)ORb, NRaRb, NRa-(1-4C) alkylene-NRaRb, NRaC(=O)Rb, NRaC(=O)NRaRb, N-(SO2-(1-4C) alkyl)2, NRa(SO2-1(1-4C) alkyl), SO2NRaRb or OSO2-trifluoromethyl;
R2 = H, halo, ORa, 1-6C alkyl, NO2, NRaRb; or

Save App's @ 1/2 of 4

R1+R2 = 3-4-membered alkylene or alkenylene chain component of a 5-6-membered ring optionally containing at least one heteroatom chosen from O, S or N;
R3 = H, halo, nitro, trifluoromethoxy, 1-6C alkyl or C(=O)ORa;
R4 = H; or
R3+R4 = 3-4-membered alkylene or alkenylene chain component of a 5-6-membered ring optionally containing at least one heteroatom;
Het = 5-6-membered heterocyclic ring containing at least one heteroatom chosen from O, S or N and optionally substituted by 1-4C alkyl;
Ra, Rb = H or 1-6C alkyl;
Rc = phenyl or 4-6C cycloalkyl optionally substituted by one or more of halo, one or more of C(=O)ORa or one or more of ORa;
n = 1-3; and
m = 1-2.

ACTIVITY - Antianginal, Hypotensive; Cardiant; Antiarteriosclerotic; Antiinflammatory; Cerebroprotective; Antiasthmatic; Antiallergic; Antiulcer; Osteopathic; Cytostatic; Vasotropic.

The hypotensive effects of 17 test compounds (I) were examined in conscious spontaneously hypertensive rats (SHR). The compounds were administered at doses of 5 mg/kg in a mixture of 5% dimethylformamide and 95% olive oil. Blood pressure was measured from a catheter inserted in the carotid artery and recorded for 5 hours after administration. The results were expressed as area-under-the-curve (AUC 0-5) (mmHg/hour) of the fall in blood pressure over time. The results ranged from 52-128 mmHg/hour.

MECHANISM OF ACTION - cGMP-specific PDE inhibitor; vasodilator; alpha -adrenergic blocker; mixed alpha , beta -blocker; alpha 2-adrenergic blocker; ACE inhibitor; NEP inhibitor; centrally acting dopaminergic agent; calcium channel blocker; diuretic.

Test compounds (I) were tested for cGMP-PDE activity using a one-step assay Wells et al. Biochim Biophys Acta 1975; 384: 430 and human recombinant PDE5. The test compounds were dissolved in dimethylsulfoxide finally present at 2% in the assay. The incubation period was 30 minutes, during which the total substrate conversion did not exceed 30%. The IC50 values were determined and ranged from 2-72 nM.

USE - The combinations are used for simultaneous, separate or sequential treatment of conditions where inhibition of cGMP-specific PDE is of therapeutic benefit including stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, congestive heart failure, acute respiratory distress syndrome, acute renal failure, chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency, post-percutaneous transluminal coronary angioplasty, carotid angioplasty, myocardial infarction, post-bypass surgery graft stenosis, peripheral vascular disease, vascular disorders, Raynaud's disease, thrombocythemia, inflammatory disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, osteoporosis, pre-teem labor, benign prostatic hypertrophy, gut motility disorder or irritable bowel syndrome, or erectile dysfunction in male or female animals (claimed).

Dwg.0/0

FILE 'HOME' ENTERED AT 14:32:20 ON 17 MAR 2006

```
=> d que stat l4; d his ful
L1               STR
```




```
REP G1=(0-10) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE
L2           113 SEA FILE=REGISTRY SSS FUL L1
L3               STR
```




```
REP G1=(0-10) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L4             0 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

100.0% PROCESSED       0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01


     (FILE 'REGISTRY' ENTERED AT 16:54:34 ON 16 MAR 2006)
                DEL HIS Y
                ACT AUD760/A
               ---------
L1               STR
L2           113 SEA SSS FUL L1
               ---------
L3               STR L1
L4             0 SEA SUB=L2 SSS FUL L3

     FILE 'REGISTRY' ENTERED AT 16:55:36 ON 16 MAR 2006
                D QUE STAT

     FILE 'CAPLUS' ENTERED AT 16:55:44 ON 16 MAR 2006
```

```
L5            46 SEA ABB=ON  PLU=ON  L2
L6             4 SEA ABB=ON  PLU=ON  L5 AND (ULCER? OR GASTROINTESTIN? OR
                 GASTR? INTESTIN?)
                 SEL HIT L6 1-4 RN
                 DEL SEL Y
L7             0 SEA ABB=ON  PLU=ON  L6 NOT (PY=>2001 OR PD=>20010810)

     FILE 'HOME' ENTERED AT 17:08:13 ON 16 MAR 2006
                 D QUE STAT L4


     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   15 MAR 2006  HIGHEST RN 877033-93-7
     DICTIONARY FILE UPDATES:  15 MAR 2006  HIGHEST RN 877033-93-7

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMI
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 16 Mar 2006  VOL 144 ISS 12
     FILE LAST UPDATED: 15 Mar 2006  (20060315/ED)
```

```
=> d his ful

     (FILE 'HOME' ENTERED AT 14:21:51 ON 17 MAR 2006)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 14:21:56 ON 17 MAR 2006
               E SPM 4757/CN
L1           2 SEA ABB=ON  PLU=ON  ("SPM 5185"/CN OR "SPM 5186"/CN)
               D CN
               D CN 2
               E "SP/W 4757"/CN 5
L2           2 SEA ABB=ON  PLU=ON  "SP/W 3672"/CN OR "SP/W 6373"/CN
L3           4 SEA ABB=ON  PLU=ON  L1 OR L2

     FILE 'REGISTRY' ENTERED AT 14:24:10 ON 17 MAR 2006
               D L3 1-4 IDE

     FILE 'CAPLUS' ENTERED AT 14:24:11 ON 17 MAR 2006
L*** DEL     31 S SPM4757 OR SPM5186 OR SPM5185 OR SPM3672 OR SPM6373 OR (S
L*** DEL      1 S L4 AND (GASTROINTESTIN? OR ULCER? OR GASTR? INTESTIN?)
L*** DEL      0 S SPW4757
L*** DEL      3 S SPW5186
               D KWIC
L*** DEL     31 S SPM4757 OR SPM5186 OR SPM5185 OR SPM3672 OR SPM6373 OR SP
L*** DEL      1 S L4 AND (GASTROINTESTIN? OR ULCER? OR GASTR? INTESTIN?)
               D QUE
               D .BEVSTR

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 14:27:26 ON 17 MAR 2006
L*** DEL      0 S L5

     FILE 'CAPLUS' ENTERED AT 14:28:32 ON 17 MAR 2006
L4          39 SEA ABB=ON  PLU=ON  L3 OR SPM4757 OR SPM5186 OR SPM5185 OR
               SPM3672 OR SPM6373 OR SPW4757 OR SPW5186 OR SPW3672 OR
               SPW6373 OR (SPM OR SP(W)W OR SPW)(W)(4757 OR 5186 OR 5185
               OR 3672 OR 6373)
L5           3 SEA ABB=ON  PLU=ON  L4 AND (GASTROINTESTIN? OR ULCER? OR
               GASTR? INTESTIN?)
               D QUE
               D 1-3 .BEVSTR

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 14:29:43 ON 17 MAR 2006
L6           0 SEA ABB=ON  PLU=ON  L5

     FILE 'CAPLUS' ENTERED AT 14:30:07 ON 17 MAR 2006
L7           9 SEA ABB=ON  PLU=ON  (NITRATOPIVAL? OR NITRATO PIVAL?)(S)EST
               ER
L8           0 SEA ABB=ON  PLU=ON  L7 AND (GASTROINTESTIN? OR ULCER? OR
               GASTR? INTESTIN?)
               D QUE

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 14:31:13 ON 17 MAR 2006
L9          59 SEA ABB=ON  PLU=ON  L7
L10         56 SEA ABB=ON  PLU=ON  L7(S)(ET OR ETHYL)
L11          4 SEA ABB=ON  PLU=ON  L10 AND (GASTROINTESTIN? OR ULCER? OR
               GASTR? INTESTIN?)
```

Searcher : Shears 571-272-2528

```
L12             4 DUP REM L11 (0 DUPLICATES REMOVED)
                  D 1-4 IBIB ABS

     FILE 'HOME' ENTERED AT 14:32:20 ON 17 MAR 2006
                 D COST
                 D QUE L3

     FILE 'REGISTRY' ENTERED AT 14:36:13 ON 17 MAR 2006
                 E "SP/W 4757"/CN 5
                 E SPW 4757/CN 5
                 E SPM 4757/CN 5
                 E "SPM-4757"/CN 5


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   15 MAR 2006  HIGHEST RN 877033-93-7
     DICTIONARY FILE UPDATES:  15 MAR 2006  HIGHEST RN 877033-93-7

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMI
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
     of this information, without the prior written consent of CAS, is
```

strictly prohibited.

FILE COVERS 1907 - 17 Mar 2006 VOL 144 ISS 13
FILE LAST UPDATED: 16 Mar 2006 (20060316/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply
They are available for your review at:

http://www.cas.org/infopolicy.html

FILE MEDLINE
FILE LAST UPDATED: 16 MAR 2006 (20060316/UP). FILE COVERS 1950 TO DA

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.ht
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 15 March 2006 (20060315/ED)

FILE EMBASE
FILE COVERS 1974 TO 17 Mar 2006 (20060317/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

The updates on February 20 and 24, 2006, were incomplete due to a technical problem. The problem has been corrected, and the missing records were included in the update on March 3, 2006. If you received SDI results from the original updates on February 20 and 24, you will automatically be credited for the update that was rerun on March 3.

If you have any questions, please contact your STN Service Center.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIDS
FILE LAST UPDATED: 15 MAR 2006 <20060315/UP>

Searcher : Shears 571-272-2528

MOST RECENT DERWENT UPDATE: 200618 <200618/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
http://scientific.thomson.com/support/products/dwpi/

>>> FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS:
http://scientific.thomson.com/support/products/dwpifv/

>>> THE CPI AND EPI MANUAL CODES WILL BE REVISED FROM UPDATE 200601. PLEASE CHECK:
http://scientific.thomson.com/support/patents/dwpiref/reftools/classif

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

FILE CONFSCI
FILE COVERS 1973 TO 25 May 2005 (20050525/ED)

CSA has suspended updates until further notice.

FILE SCISEARCH

FILE COVERS 1974 TO 16 Mar 2006 (20060316/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE JICST-EPLUS
FILE COVERS 1985 TO 13 MAR 2006 (20060313/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE JAPIO
FILE COVERS APR 1973 TO OCTOBER 27, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE. USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHE DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION ABOUT THE IPC REFORM <<<

Searcher : Shears 571-272-2528